Intercept Pharmaceuticals's Chief Accounting Officer just declared owning 14,318 shares of Intercept Pharmaceuticals

Rocco Venezia, Intercept Pharmaceuticals's Chief Accounting Officer, has just filed an initial statement of beneficial ownership where 14,318 shares of Intercept Pharmaceuticals were declared. This form is usually filed as a prelude to receiving options or buying company shares, so there may be more to come from Venezia. Venezia operates out of New York, NY. Some additional info was provided as follows:


Includes both restricted stock units that represent a contingent right to receive one share of the Issuer's Common Stock, as well as shares of Common Stock.
The award is fully vested.
The award is fully vested.
The award is subject to a four-year vesting period, with 25% of the shares subject to the award vesting and becoming exercisable in an initial inst allment on the anniversary of the Vesting Commencement Date and 1/48th of the shares subject to the award vesting and becoming exercisable each month thereafter. The Vesting Commencement Date is January 1, 2018.
The award is subject to a four-year vesting period, with 25% of the shares subject to the award vesting and becoming exercisable in an initial installment on the anniversary of the Vesting Commencement Date and 1/48th of the shares subject to the award vesting and becoming exercisable each month thereafter. The Vesting Commencement Date is January 1, 2019.
The award is subject to a four-year vesting period, with 25% of the shares subject to the award vesting and becoming exercisable in an initial installment on the anniversary of the Vesting Commencement Date and 1/48th of the shares subject to the award vesting and becoming exercisable each month thereafter. The Vesting Commencement Date is January 1, 2020.
The award is subject to a four-year vesting period, with 25% of the shares subject to the award vesting and becoming exercisable in an initial installment on the anniversary of the Vesting Commencement Date and 1/48th of the shares subject to the award vesting and becoming exercisable each month thereafter. The Vesting Commencement Date is January 1, 2021.

The above information was disclosed in a filing to the SEC. To see the filing, click here.

To receive a free e-mail notification whenever Intercept Pharmaceuticals makes a similar move, sign up!

Other recent filings from the company include the following:

Intercept Pharmaceuticals's Chief Qual. Officer & SVP Ops. just disposed of 2,455 shares - Jan. 13, 2022
Departure of Directors or Certain - Jan. 10, 2022
Intercept Pharmaceuticals's President & CEO just disposed of 5,941 shares - Jan. 4, 2022
Statement of changes in beneficial ownership of securities - Jan. 4, 2022
SVP of Intercept Pharmaceuticals just disposed of 2,455 shares - Jan. 4, 2022

Auto Refresh

Feedback